EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study

Klaus Geissler iD, Zdenek Koristek, Teresa Bernal Del Castillo iD, Jan Novák, Gabriela Rodríguez-Macías, Stephan K Metzelder, Arpad Illes, Jiří Mayer, Montserrat Arnan, Mary-Margaret Keating, Jürgen Krauter, Monia Lunghi und 7 weitere

British Journal of Haematology · 2024-11 · 205 (5) · 1734-1745

DOI: 10.1111/bjh.19741 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Haematology, online erschienen am 23.09.2024. Verfasst von Klaus Geissler und 18 weiteren Autor:innen. Beteiligte Einrichtung: Sigmund Freud PrivatUniversität, Wien, Austria. Hauptthemen laut MEDLINE: Decitabine, Leukemia, Myeloid, Acute, Uridine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Astex Pharmaceuticals, Inc., now part of Taiho Oncology, Inc., Astex Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study compared decitabine exposure when administered IV (DEC‐IV) at a dose of 20 mg/m 2 for 5‐days with orally administered decitabine with cedazuridine (DEC‐C), as well as the clinical efficacy and safety of DEC‐C in patients with acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. In all, 89 patients were randomised 1:1 to DEC‐IV or oral DEC‐C (days 1–5 in a 28‐day treatment cycle), followed by 5 days of the other formulation in the next treatment cycle. All patients received oral DEC‐C for subsequent treatment cycles until treatment discontinuation. Equivalent systemic decitabine exposures were demonstrated (5‐day area under the curve ratio between the two decitabine formulations of 99.64 [90% confidence interval 91.23%, 108.80%]). Demethylation rates also were similar (≤1.1% difference). Median overall survival (OS), clinical response and safety profile with oral DEC‐C were consistent with those previously observed with DEC‐IV. Next‐generation sequencing was performed to identify molecular abnormalities that impact OS and TP53 mutations were associated with a poor outcome. These findings support the use of oral DEC‐C in patients with AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DecitabineLeukemia, Myeloid, AcuteUridineAntineoplastic Combined Chemotherapy ProtocolsHumansMaleMiddle AgedFemaleAdministration, OralAgedAdultCross-Over StudiesAged, 80 and overAdministration, IntravenousTreatment Outcome

Stichwörter der Autor:innen

DNA methyltransferase inhibitorsacute myeloid leukaemiadecitabine/cedazuridinehypomethylating agentssomatic mutations

Substanzen

DecitabineUridinecedazuridine

Autor:innen und Institutionen

  • Sigmund Freud PrivatUniversität, Wien, Austria.
  • Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
  • Hospital Universitario Central de Asturias, Instituo de Investigación Sanitaria del Principado de Asturias, Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.
  • Department of Haematology, Third Faculty of Medicine, Charles University and Faculty Hospital University, Hospital Královské Vinohrady, Prague, Czech Republic.
  • Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Philipps University Marburg and University Hospital Gießen and Marburg, Marburg, Germany.

ORCID-Profile: Klaus Geissler, Teresa Bernal Del Castillo, Valeria Santini, Harold Keer, Michael Lübbert

Förderung

  • Astex Pharmaceuticals, Inc., now part of Taiho Oncology, Inc.
  • Astex Pharmaceuticals

Zitieren

APA

Geissler, K., Koristek, Z., Del Castillo, T. B., Novák, J., Rodríguez-Macías, G., Metzelder, S. K., Illes, A., Mayer, J., Arnan, M., Keating, M. M., Krauter, J., Lunghi, M., Fracchiolla, N. S., Platzbecker, U., Santini, V., Sano, Y., Oganesian, A., Keer, H., & Lübbert, M. (2024). Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. British Journal of Haematology, 205(5), 1734-1745. https://doi.org/10.1111/bjh.19741

Vancouver

Geissler K, Koristek Z, Del Castillo TB, Novák J, Rodríguez-Macías G, Metzelder SK, et al. Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. British Journal of Haematology. 2024;205(5):1734-1745. doi:10.1111/bjh.19741

BibTeX
@article{Geissler2024,
  author = {Geissler, Klaus and Koristek, Zdenek and Del Castillo, Teresa Bernal and Novák, Jan and Rodríguez-Macías, Gabriela and Metzelder, Stephan K and Illes, Arpad and Mayer, Jiří and Arnan, Montserrat and Keating, Mary-Margaret and Krauter, Jürgen and Lunghi, Monia and Fracchiolla, Nicola Stefano and Platzbecker, Uwe and Santini, Valeria and Sano, Yuri and Oganesian, Aram and Keer, Harold and Lübbert, Michael},
  title = {Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {205},
  number = {5},
  pages = {1734--1745},
  doi = {10.1111/bjh.19741}
}
Kostenlos starten →